JAMA Network
About The Study: In critically ill patients with sepsis, compared with intermittent administration, the continuous administration of the antibiotic meropenem did not improve the composite outcome of mortality and emergence of pandrug-resistant or extensively drug-resistant bacteria at day 28.
Authors: Giovanni Landoni, M.D., of the IRCCS San Raffaele Scientific Institute in Milan, Italy, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2023.10598)
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
